Migraine Induction Properties of PACAP-38 After Eptinezumab in Migraine Without Aura Patients.

• Status: Recruiting
• Trial end date: 2023-07-30
• Target enrollment: 0
• Participant gender: All

Summary

To investigate whether administration of calcitonin gene-related peptide (CGRP) binding monoclonal antibodies eptinezumab prevents pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38) induced migraine attacks in migraine without aura patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Danish Headache Center
• Treatments: Pituitary Adenylate Cyclase-Activating Polypeptide

Criteria

Inclusion Criteria:

• Healthy volunteers of both sexes.

• 18-60 years.

• 50-100 kg.

• Women of childbearing potential must use adequate contraception

• History of migraine without aura for ≥ 12 months according to the International Classification of Headache Disorders 3rd Edition (ICHD-3) criteria.

• No migraine preventive treatment.

Exclusion Criteria:

• A history of serious somatic disease

• > 50 years of age at migraine onset.

• History of any other primary headaches disorder (except ≤ 5 monthly days with tension- type headache).

• Daily intake of any medication except contraceptives